Global Implantable Infusion Pump Market Set for Steady Growth from 2022 to 2032, Driven by Chronic Disease Management and Technological Advances.

The autoinjector offers potential pain relief and is designed for self-administration, eliminating the need for refrigeration ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

Q1 2025 Earnings Call Transcript May 13, 2025 Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Acumen Pharmaceuticals Inc (ABOS) showcases rapid study enrollment and promising biomarker developments, despite reporting a net loss and facing competitive pressures in Alzheimer's research.

Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration ...

Liquidia Corporation’s LQDA share price has surged by 6.66%, which has investors questioning if this is right time to sell.

The subcutaneous version of $25 billion-a-year ... and limit the impact when biosimilars of the intravenous versions eventually reach the market. BMS - which has predicted Opdivo will lose market ...

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...